Lexeo Therapeutics Inc. (LXEO)
Market Closed
17 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
4. 69
+0.13
+2.8509%
$
362.77M Market Cap
- P/E Ratio
- Div Yield
721,472 Volume
- Eps
$ 4.56
Previous Close Want to track LXEO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
LXEO closed today higher at $4.69, an increase of 2.8509% from yesterday's close, completing a monthly decrease of -8.2192% or -$0.42. Over the past 12 months, LXEO stock lost -52.8643%.
LXEO is not paying dividends to its shareholders.
The last earnings report, released on Mar 23, 2026, exceeded the consensus estimates by 0.3148%. On average, the company has surpassed earnings expectations by 0.4449%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Seekingalpha | 2 weeks ago
Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline
Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027.
Seekingalpha | 3 weeks ago
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript
Seekingalpha | 1 month ago
Lexeo Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 1 | $10 | $4.63 | -$5.37 | -53.7% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,000 | $5,740 | $4,560 | -$1,180 | -20.56% |
| BG Bart Gancher Intech Investment Management LLC | 16,504 | $108,417.31 | $75,113 | -$33,304.31 | -30.72% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.68M | $10.05M | $7.65M | -$2.4M | -23.86% |
 David Kim Paradigm Biocapital Advisors LP | 6.18M | $55.45M | $28.15M | -$27.31M | -49.24% |
Lexeo Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Geulah Livshits Chardan Capital | 3,087.24 | $14,664.39 | $14,633.52 | -$30.87 | -0.21% |
Lexeo Therapeutics Inc. (LXEO) FAQ
What is the stock price today?
The current price is $4.69.
On which exchange is it traded?
Lexeo Therapeutics Inc. is listed on NASDAQ (NMS).
What is its stock symbol?
The ticker symbol is LXEO.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 362.77M.
Has Lexeo Therapeutics Inc. ever had a stock split?
No, there has never been a stock split.
Lexeo Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | R. Nolan Townsend CEO | NASDAQ (NMS) Exchange | 52886X107 CUSIP |
| US Country | 59 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Lexeo Therapeutics, Inc., founded in 2017 and headquartered in New York, New York, positions itself as a pioneering force in the realm of genetic medicine, focusing its efforts on the development of treatments for both inherited and acquired diseases. Operating at the clinical stage, Lexeo Therapeutics harnesses groundbreaking technologies to create gene therapy solutions aimed at confronting and potentially curing a variety of complex medical conditions.
Products and Services
- LX2006: This advanced AAVrh10-based gene therapy candidate is designed specifically for the treatment of cardiomyopathy associated with Friedreich's ataxia (FA), a challenging and life-shortening condition. By targeting the genetic root of the disease, LX2006 aims to provide a significant therapeutic benefit.
- LX2020: Developed as an AAVrh10-based gene therapy, LX2020 targets plakophilin-2 arrhythmogenic cardiomyopathy, a genetic disorder that affects the heart muscle. This candidate is part of Lexeo’s dedication to addressing rare cardiac conditions at the genetic level.
- LX2021: Focused on combating DSP cardiomyopathy, LX2021 represents another facet of Lexeo’s gene therapy strategies. This candidate is specifically geared towards tackling the dsp gene mutations, illustrating the company's versatile approach to genetic medicine.
- LX2022: Targeting hypertrophic cardiomyopathy (HCM) caused by mutations in the TNNI3 gene, LX2022 is at the forefront of gene therapy research aimed at this common form of heart muscle thickening, showcasing Lexeo’s commitment to addressing a range of genetic cardiac diseases.
- LX1001: As an AAVrh10-based gene therapy, LX1001 is designed for patients homozygous for APOE4, a known genetic risk factor for Alzheimer's disease, indicating Lexeo’s foray into neurogenetic treatments.
- LX1020 and LX1021: These gene therapy candidates expand Lexeo’s portfolio into the treatment of APOE4 homozygous conditions, underscoring the company’s dedication to leveraging genetic insights for therapeutic innovation.
- LX1004: Dedicated to the treatment of CLN2 Batten disease, LX1004 is an AAVrh10-based gene therapy candidate that signifies Lexeo’s commitment to combatting rare neurodegenerative disorders through advanced gene therapy solutions.
Contact Information
Address: 345 Park Avenue South
Phone: 212-547-9879
Website: https://www.lexeotx.com
